GH Research (NASDAQ:GHRS) Trading Down 0.9% – Should You Sell?

GH Research PLC (NASDAQ:GHRS) shares traded down 0.9% on Thursday . The stock traded as low as $8.64 and last traded at $8.64. 12,976 shares were traded during trading, a decline of 84% from the average session volume of 79,088 shares. The stock had previously closed at $8.72.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of GH Research in a report on Thursday, September 5th. JMP Securities reaffirmed a “market outperform” rating and issued a $39.00 price objective on shares of GH Research in a report on Wednesday, September 4th.

GH Research Price Performance

The firm has a 50-day moving average of $7.85 and a 200-day moving average of $10.47. The stock has a market cap of $451.60 million, a PE ratio of -12.90 and a beta of 0.74.

GH Research (NASDAQ:GHRS) last issued its earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. Equities analysts forecast that GH Research PLC will post -0.85 EPS for the current fiscal year.

Hedge Funds Weigh In On GH Research

An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP raised its holdings in shares of GH Research PLC (NASDAQ:GHRS) by 19.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,966,726 shares of the company’s stock after purchasing an additional 656,163 shares during the quarter. GH Research accounts for approximately 16.7% of Lynx1 Capital Management LP’s investment portfolio, making the stock its 3rd largest holding. Lynx1 Capital Management LP owned approximately 7.62% of GH Research worth $46,252,000 as of its most recent SEC filing. 56.90% of the stock is owned by institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).